| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry | European Journal of Nuclear Medicine and Molecular Imaging |
| 131 | 2017 |
| Patient-specific dosimetry in peptide receptor radionuclide therapy: a clinical review | Australasian Physical & Engineering Sciences in Medicine | 12 | 2015 | |
| Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours | European Journal of Nuclear Medicine and Molecular Imaging |
| 72 | 2004 |
| Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship | 2005 | |||
| New advances in peptide receptor radionuclide therapy | 2002 |
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four treatment cycles | European Journal of Nuclear Medicine and Molecular Imaging |
| 2023 | |
| Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope? | Acta Pharmaceutica Sinica B |
| 45 | 2023 |
| Updating 90Y Voxel S-Values including internal Bremsstrahlung: Monte Carlo study and development of an analytical model | Physica Medica |
| 2023 | |
| Radioactivity of biological samples of patients treated with 90Y-DOTATOC | Nuclear Engineering and Technology |
| 2023 | |
| Interaction of Radiopharmaceuticals with Somatostatin Receptor 2 Revealed by Molecular Dynamics Simulations | Journal of Chemical Information and Modeling |
| 1 | 2023 |